The physicians looked at several clinical trials to create evidence-based guidelines. They found a loading phase of three monthly injections of ranibizumab 0.5 mg, an anti-angiogenic that has been approved to treat ARMD, provided the best improvement in visual acuity. They also found starting treatment within two weeks of diagnosis provided the best outcome, and waiting more than one month to start treatment led to further vision loss.
Related Articles on Ophthalmology:
BIOLASE Laser Technology Issued Patent to Treat Eye Conditions
Vision Treatment Company AcuFocus Raises $65M in Funding
Cataract Surgery Gains Popularity as Surgical Option for Glaucoma
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.